The Evolving Landscape of Myeloma Treatment: A Decade of Progress
For years, a cancer diagnosis was often spoken of in hushed tones, referred to as a “bad illness” or a “long illness.” Today, the narrative is shifting. Cancer is increasingly curable, and with it, the language is evolving. This transformation is fueled by relentless research, even for cancers that once seemed insurmountable. In 2025, Italy is projected to spot approximately 390,000 new cancer diagnoses, but this figure is accompanied by a decreasing trend and a 9% overall reduction in deaths over the last decade.
A Dramatic Increase in Survival Rates for Multiple Myeloma
The outlook for multiple myeloma has dramatically improved. From 2015 to the present, life expectancy for those diagnosed with the disease has risen from two and a half years to nearly ten years. This is significant for patients and their families. Italy currently sees around 6,590 new cases annually, predominantly affecting individuals over 70, with a slightly higher incidence in men.
Understanding Multiple Myeloma: Symptoms and Diagnosis
Multiple myeloma can initially manifest as acute bone pain or persistent back pain that doesn’t respond to anti-inflammatory medications. Some individuals experience unexplained fractures, kidney problems, or frequent infections. Anemia often serves as an early warning sign, prompting the need for thorough diagnostic investigations.
Multiple myeloma is a cancer of the blood that profoundly impacts a patient’s life. It originates in the bone marrow and targets plasma cells, white blood cells crucial for immune defense. When these cells undergo genetic transformation, they multiply uncontrollably, disrupting the bone marrow’s balance and hindering the production of healthy cells. This can lead to anemia, coagulation issues, increased susceptibility to infections, and bone lesions. Cancerous plasma cells produce abnormal antibodies, known as monoclonal proteins, which are ineffective for the immune system and potentially harmful.
The Role of Relapse and the Pursuit of Minimal Residual Disease
Relapses are not uncommon in multiple myeloma, and each recurrence can be more challenging. However, advancements in research have led to a wider range of therapies, shifting the approach from resignation to proactive management. Healthcare professionals are now more confident in administering treatments that are well-tolerated and can maintain a good quality of life for extended periods. A frequent question from patients is about the future – will they be present for important family events? The response is increasingly optimistic.
The Future of Myeloma Treatment: Immunotherapy and Beyond
Immunotherapy represents the new frontier in cancer treatment, and in the case of multiple myeloma, it aims to both target myeloma cells and restore the body’s immune response. Monoclonal antibodies were the first form of immunotherapy used to treat multiple myeloma. Antibody-drug conjugates (ADCs), such as belantamab mafodotin, have since been approved by the European Medicines Agency and are awaiting regulatory approval from the Italian Medicines Agency (AIFA). These conjugates deliver potent cytotoxic agents directly to tumor cells, offering both efficacy and tolerability.
“Multiple myeloma isn’t a single disease,” explains Silvia Mangiacavalli, hematologist at the Hematology U.O.C. Of the IRCCS Fondazione Policlinico San Matteo in Pavia. “Today, we can extend patients’ lives, and our goal is to keep people out of the hospital with a good quality of life and the ability to craft and realize plans for the future.”
Alessandro Corso adds, “Advances in research have yielded exceptionally good results for patients. We expect to achieve long-term disease control and improve quality of life. One of our goals is to reach so-called MRD, minimal residual disease, to be able to suspend therapy. This has already happened in hematology, so it’s not an unrealistic dream.”
FAQ
- What are the early signs of multiple myeloma? Bone pain, back pain, unexplained fractures, kidney problems, frequent infections, and anemia.
- What is the role of immunotherapy in myeloma treatment? Immunotherapy aims to target myeloma cells and restore the body’s immune response.
- What is MRD and why is it important? MRD, or minimal residual disease, refers to the small number of cancer cells remaining after treatment. Achieving MRD allows for the possibility of suspending therapy.
Pro Tip: Early detection is crucial. If you experience persistent, unexplained symptoms, consult your doctor for a thorough evaluation.
Explore more articles on cancer treatment and prevention on our website. Subscribe to our newsletter for the latest updates and insights.
